Women's Health

The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

Bayer announced 12 presentations focused on symptoms of menopause and effects of its investigational oral nonhormonal medication elinzanetant.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.

Your daily dose of the clinical news you may have missed.

The most common harm associated with breast cancer screening is a false positive finding; this UC Davis expert wanted to know more about how women respond.

Your daily dose of the clinical news you may have missed.

Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.

Less than 15% of women with menopause receive treatment for VMS, suggesting a need a for more education and awareness, according to JoAnn Pinkerton, MD.

An expert discussion with JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program of elinzanetant for moderate-to-severe VMS.

Breast cancer will claim the lives of more than 42 000 women in 2024. The primary care clinician's role as advocate for screening mammography can not be overemphasized.

JoAnn Pinkerton, MD, national lead for the OASIS clinical trial program evaluating elinzanetant for menopausal VMS, discusses how non-hormonal therapy differs from HRT.

Use of menopausal hormone therapy decreased from nearly 27% to 5% among postmenopausal women between 1999 and 2020, according to new research.

Your daily dose of the clinical news you may have missed.

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

The risk of gestational diabetes was 2-fold greater among young women with prediabetes before conceiving compared with those who had normoglycemia.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.

FDA heightened label warnings about hepatic injury and increased the required frequency of liver function testing after initiation of fezolinetant.

New data shows that favorable CV health in the first trimester is associated with a 35% to 62% lower risk of HDP regardless of level of genetic risk.

Those least likely to schedule further screening mammograms had received a false-positive with recommendation for follow-up after only a short interval.

Regulations have been amended under the Mammography Quality Standards Act of 1992 to ensure women receive quality mammography for early breast cancer detection and prevention.

Your daily dose of the clinical news you may have missed.

Obstructive sleep apnea during pregnancy increases risk for gestational hypertension and preeclampsia; CPAP therapy may lower risk significantly.

The submission is based on data from OASIS trials that showed elinzanetant significantly reduced the frequency and severity of moderate-to-severe VMS associated with menopause.